Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability (Q37104344)

18 August 2017

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability (English)

1 reference

18 August 2017

0 references

1 reference

2

Luigi Ferrucci

1 reference

18 August 2017

1

H Ballentine Carter

1 reference

18 August 2017

4

Patricia Landis

1 reference

18 August 2017

6

Jonathan I Epstein

1 reference

18 August 2017

Anna Kettermann

3

1 reference

18 August 2017

E James Wright

series ordinal

5

1 reference

18 August 2017

Bruce J Trock

series ordinal

7

1 reference

18 August 2017

E Jeffrey Metter

series ordinal

8

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Journal of the National Cancer Institute

18 August 2017

1 reference

18 August 2017

98

1 reference

18 August 2017

21

1 reference

18 August 2017

1521-1527

1 reference

More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Prostate cancers in men with low PSA levels--must we find them?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645644

Nonparametric Estimation from Incomplete Observations

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ410

Rate of Change in Serum Prostate Specific Antigen Levels as a Method For Prostate Cancer Detection

21 January 2018

1 reference

12 December 2020

PSA velocity for the diagnosis of early prostate cancer. A new concept

1 reference

12 December 2020

Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen

1 reference

12 December 2020

Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJJ410

1 reference

release_ef6mahsqobexvozf22toip4asu

18 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ef6mahsqobexvozf22toip4asu

24 November 2022

mapped directly with Wikidata item

1 reference

18 August 2017

PubMed publication ID

17077354

1 reference